Novo Nordisk A/S (NVO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: lowered sales and profit growth outlooks, market share loss in the GLP-1 market, and challenges in the U.S. obesity market. Despite some optimistic guidance and strategic initiatives, the lowered growth expectations and uncertainties in regulatory approvals and market dynamics create a negative sentiment, likely leading to a stock price decline of -2% to -8%.
Key Financial Performance
Sales Growth 15% sales growth in the first 9 months of 2025, driven by both U.S. operations (15% growth) and international operations (16% growth). Sales growth was positively impacted by one-offs in the U.S. of around DKK 6 billion.
Operating Profit Growth 10% operating profit growth in the first 9 months of 2025. Adjusted operating profit (excluding restructuring costs) increased by 16% in Danish kroner and 21% at constant exchange rates.
Gross Margin Decreased to 81.0% compared to 84.6% in 2024. The decline was mainly due to DKK 3 billion in one-off restructuring costs and impairments related to production assets, as well as costs from capacity expansions.
Insulin Sales Increased by 3%, driven by U.S. operations growing 18%. The increase was positively impacted by gross-to-net adjustments related to prior years and channel/payer mix, partially offset by a decline in volume.
Obesity Care Sales Increased by 41%, driven by U.S. operations growing 24% and international operations growing 83%. Sales of Wegovy reached approximately DKK 20 billion, growing at 168%.
Rare Disease Sales Increased by 13%, driven by sales growth in the U.S. (14%) and international operations (13%).
Free Cash Flow Decreased to DKK 63.9 billion compared to DKK 71.8 billion in the first 9 months of 2024, driven by increased capital expenditures.
Net Profit Increased by 4%, with diluted earnings per share increasing by 4% to DKK 16.99.
Restructuring Costs DKK 9 billion in costs related to restructuring were booked in the third quarter, expected to drive approximately DKK 8 billion in annual savings by the end of 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Rybelsus approval: Rybelsus is now approved in the U.S. and EU with CV indications based on the SOUL trial.
Mim8 submission: Mim8 has been submitted for regulatory approval in both U.S. and EU.
Cagrilintide: Phase III data for cagrilintide from REDEFINE 1 shows 11.8% weight loss at 68 weeks, with further studies planned.
Wegovy pill: FDA decision for Wegovy pill expected by end of 2025, with launch planned for early 2026.
GLP-1 market share: Novo Nordisk remains the market leader in international operations with a volume market share of 68%.
Wegovy expansion: Wegovy is now launched in more than 45 countries, with plans for further expansion.
Metsera acquisition proposal: Novo Nordisk submitted a proposal to acquire Metsera for up to USD 10 billion to enhance its diabetes and obesity portfolio.
Company-wide transformation: A transformation program is underway to simplify operations, accelerate decision-making, and reallocate resources, including a reduction of 9,000 positions globally, expected to save DKK 8 billion annually by 2026.
Sales growth: Sales grew by 15% in the first 9 months of 2025, driven by GLP-1 products and obesity care.
Cost restructuring: DKK 9 billion in restructuring costs were booked, impacting gross margin and operating profit.
Focus on core areas: Novo Nordisk is sharpening its focus on diabetes, obesity, and related comorbidities, discontinuing non-core projects like stem cell research for Parkinson's disease.
R&D acquisitions: Acquired Akero and Omeros' zaltenibart assets to strengthen its pipeline in obesity and rare diseases.
Telehealth expansion: Plans to expand telehealth capabilities across markets to meet evolving consumer behavior.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Lower growth expectations for GLP-1 treatments: The company has revised its sales growth expectations for GLP-1 treatments in diabetes and obesity downward, citing intensifying competition and pricing pressures in both U.S. and international markets.
Restructuring and workforce reduction: A company-wide transformation program will result in the reduction of approximately 9,000 positions globally, aiming to save DKK 8 billion annually by 2026. This restructuring has significant human and operational impacts.
Regulatory and Medicaid coverage challenges: Several U.S. states have announced changes to Medicaid coverage for obesity medicines due to budgetary concerns, which will affect access to Wegovy in 2026.
Compounded GLP-1 products: The rise of compounded GLP-1 products in the U.S. market, with over 1 million patients using them, poses a competitive and regulatory challenge.
Gross margin decline: The gross margin decreased to 81.0% from 84.6% in 2024, impacted by restructuring costs, impairments, and costs related to capacity expansions.
Patent expiry risks: The compound patent expiry of the semaglutide molecule in certain countries is expected to negatively impact global sales growth in 2026.
Inflation Reduction Act impact: The acceptance of the Inflation Reduction Act maximum fair price for key products in Medicare Part D will have a negative low single-digit impact on global sales growth starting in 2027.
Operational and R&D cost pressures: Increased R&D and operational costs, including those related to acquisitions and restructuring, are impacting profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Sales Growth: Sales growth for 2025 is expected to be 8% to 11% at constant exchange rates, reflecting lower expectations for GLP-1 treatments in diabetes and obesity. Sales growth reported in Danish kroner is expected to be around 4 percentage points lower than constant exchange rate growth.
Operating Profit: Operating profit for 2025 is expected to grow by 4% to 7% at constant exchange rates, negatively impacted by DKK 8 billion in restructuring costs. Growth reported in Danish kroner is expected to be around 6 percentage points lower than at constant exchange rates.
Capital Expenditure: Capital expenditure for 2025 is now expected to be around DKK 60 billion, driven by adjustments to expansion plans.
Free Cash Flow: Free cash flow is now expected to be DKK 20 billion to DKK 30 billion, reflecting lower-than-expected trade receivables in the U.S. and reduction in capital expenditure.
Future Impact of Patent Expiry: The compound patent expiry of semaglutide molecule in certain countries in international operations is expected to have an estimated negative low single-digit impact on global sales growth in 2026.
Impact of Acquisitions: The agreed acquisition of Akero is expected to lead to increased R&D costs with an estimated negative impact on full-year operating profit growth of around 3 percentage points in 2026, depending on the timing of closing.
Medicare Part D Pricing Impact: Novo Nordisk accepted the Inflation Reduction Act maximum fair price (MFP) for Ozempic, Rybelsus, and Wegovy in Medicare Part D for 2027. The estimated direct impact of semaglutide MFP in Medicare Part D, had it been introduced on January 1, 2025, would have been a negative low single-digit impact on global sales growth for the full year of 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Payments: In the first 9 months of 2025, Novo Nordisk returned DKK 53 billion to shareholders, mainly through dividend payments.
Share Buyback: No specific mention of a share buyback program was made in the transcript.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What strategic initiatives are being considered to address the 9 percentage point market share loss in the GLP-1 market?
A:The company is focusing on expanding its pipeline through internal activities and acquisitions, controlling costs, and increasing commercial partnerships with entities like Costco, Walmart, GoodRx, LifeMD, and Ro. They are also launching new products like the Wegovy pill to expand the market. However, these measures will take time to show results.
Q:How is the company planning to manage significant cash outflows from acquisitions and other financial obligations?
A:The company has a consistent capital allocation framework that prioritizes investing in the business, paying dividends, adding to the pipeline through business development and M&A, and share buybacks if there is excess cash. They aim to convert earnings into cash flow and focus on value-generating opportunities.
Q:What is the company's response to concerns about pursuing Metsera and its implications for the internal pipeline?
A:The company is excited about its internal pipeline but believes no pipeline is broad enough to meet its ambition of treating hundreds of millions of people. The Metsera acquisition supports their long-term strategy as the assets are differentiated and complementary to their portfolio.
Q:Can the company confirm if it has been contacted by the FTC regarding Metsera?
A:The company did not provide details but stated that they are confident the deal can close according to regulations and have conducted comprehensive due diligence with external experts.
Q:What is the company's view on Medicare coverage for obesity and the potential risks from the IRA?
A:The company sees Medicare coverage for obesity as a significant opportunity, with 30 million people of Medicare age suffering from obesity. However, they cannot speculate on the potential impact. Regarding the IRA, they are under confidentiality with CMS and cannot comment further.
Q:Why has the company lost market share in the GLP-1 market, and what are the contributing factors?
A:Market dynamics vary by region. In China, the market is not growing as expected, and the company is losing in the online segment due to restrictions on selling Wegovy online. In Europe, some markets like the UK show positive trends. The company anticipated losing market share as competitors entered the market, but they remain optimistic about long-term volume growth.
Q:What is the company's device strategy, particularly regarding Wegovy FlexTouch and other devices?
A:The company is exploring other presentations, including vials and devices, to provide more options. They are in active dialogue with the FDA regarding Wegovy FlexTouch but cannot comment on timelines.
Q:How is the company planning for the launch of the Wegovy pill, and what are the pricing considerations?
A:The company is excited about the Wegovy pill and plans to make it available in all channels, including Medicaid, Medicare, commercial, and cash offerings. They are focusing on competitive pricing and leveraging telehealth partnerships for the launch.
Q:What are the company's high-level thoughts on 2026 growth and financial factors?
A:The company highlighted several factors: a 2% gross-to-net favorability in 2023 that will not repeat, low single-digit sales impact from loss of exclusivity in certain markets, the launch of the Wegovy pill, and a 3% negative impact on operating profit growth from the Akero acquisition.
Q:What is the company's view on Metsera's differentiation and the risks associated with the deal structure?
A:The company sees Metsera as complementary to its pipeline in terms of efficacy, safety, scalability, and dosing frequency. They are confident in the deal structure and believe the assets are valuable even if they only acquire 50% of the company.
Q:What are the obstacles to better penetration in the U.S. commercial channel for obesity drugs?
A:The main obstacles are the quality of access, intense competition, and the rise of compounding. The company is investing in improving access and expanding the cash channel through partnerships.
Q:What is the company's approach to telehealth partnerships and addressing compounding issues?
A:The company is in discussions with multiple telehealth providers to expand access and is focused on addressing the safety concerns of illicit APIs used by compounders. They have partnerships with entities like Costco, Walmart, and EMed.
Q:How important is the REDEFINE 4 study for differentiation, and will the company launch CagriSema if the study shows no significant difference?
A:The company sees REDEFINE 4 as important for potential differentiation but considers non-inferiority with upside on gastrointestinal side effects and CV benefits as a base case. They plan to launch CagriSema even if the study shows no statistically significant difference.
Q:What are the company's plans for launching the Wegovy pill outside the U.S.?
A:The company prioritizes the U.S. launch but is prepared to launch in select international markets in 2026. They plan to leverage their experience with Rybelsus and telehealth channels to support the launch.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to questions about FTC involvement in the Metsera deal, specific pricing strategies for the Wegovy pill, and the potential impact of Medicare coverage and IRA regulations. They also did not provide clear timelines for the Wegovy FlexTouch device or detailed differentiation data for Metsera.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CVRs
DKK restructuring
Executive VP
FGF analog
GLP sale
GLP treatment
MFP
Medicare
Member slide
Metsera
Omeros
Ozempic
PNH
Phase II
Phase III
Product Portfolio
REIMAGINE study
RENEW
SYNCHRONY program
USD share
acquisition
agreement
cagrilintide
capability
closing
commitment
core
efruxifermin
fibrosis
impairment
pill
project
resource
transformation
treatment option
type diabetes
NVO Transcript
Novo Nordisk A/S (NOVO:CA) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals mixed sentiments: strong product uptake and successful launches contrast with challenges like U.S. price erosion and supply limitations. Despite positive product feedback and strategic international expansion, the negative growth outlook for U.S. operations and expected decline in sales and operating profit are concerning. The Q&A highlights potential risks with patent expirations and competition. Overall, the sentiment is balanced with both positive developments and significant challenges, leading to a neutral outlook.
Novo Nordisk A/S (NOVO:CA) Q4 2025 Earnings Call Transcript
Unknown2-5
The earnings call summary indicates a mixed outlook. While there are positive elements such as a 16% increase in Wegovy sales and optimistic guidance for Wegovy pill demand, there are also concerns about declining U.S. sales and significant restructuring costs. The Q&A reveals uncertainties in volume uplift and market dynamics, particularly in the obesity sector. These mixed signals, along with stable but not exceptional financial metrics, suggest a neutral sentiment, expecting minimal stock price movement in the short term.
Novo Nordisk A/S (NVO) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals several concerns: lowered sales and profit growth outlooks, market share loss in the GLP-1 market, and challenges in the U.S. obesity market. Despite some optimistic guidance and strategic initiatives, the lowered growth expectations and uncertainties in regulatory approvals and market dynamics create a negative sentiment, likely leading to a stock price decline of -2% to -8%.
Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Transcript
Positive8-6
The earnings call reflects strong financial performance with an 18% sales growth and 20% operating profit increase. The company's strategic initiatives, such as partnerships and market expansions, are promising. While there are some uncertainties in litigation and pricing strategies, management's confidence in growth, particularly in China, and the launch of new products like oral Wegovy, supports a positive outlook. The guidance suggests continued strong performance, and there's optimism in overcoming challenges like LOE impacts. Overall, the sentiment is positive, with potential for stock price appreciation.
NVO Slides
NVO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
